IDEAYA Biosciences Newsroom

Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $55

Futu NewsDec 23 21:32 · Ratings

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and IDEAYA Biosciences (IDYA)

TipRanksDec 23 21:01 · Ratings

Companies Like IDEAYA Biosciences (NASDAQ:IDYA) Are In A Position To Invest In Growth

Simply Wall StDec 20 19:20

IDEAYA Biosciences (IDYA) Receives a Hold From Leerink Partners

TipRanksDec 18 13:37 · Ratings

RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61

Futu NewsDec 18 01:31 · Ratings

Cantor Fitzgerald Reiterates Overweight on IDEAYA Biosciencesto Overweight

BenzingaDec 17 22:03

IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush

Dow JonesDec 17 21:44 · Ratings

IDEAYA Biosciences Analyst Ratings

BenzingaDec 17 21:30 · Ratings

LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65

Futu NewsDec 17 19:31 · Ratings

The Independent Data Monitoring Committee Has Recommended Move-Forward Dose And The Completion Of Part 2A Dose Optimization For Ideaya Biosciences' Phase 2/3 Trial Of Darovasertib And Crizotinib Combination In First-line HLA-A2-Negative Metastatic...

BenzingaDec 17 19:05

Express News | IDEAYA Biosciences Inc - Targets Phase 3 Study for Uveal Melanoma in First Half of 2025

BreakingsDec 17 19:01

Express News | IDEAYA Announces Idmc Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L Hla-a2-Negative Metastatic Uveal Melanoma

BreakingsDec 17 19:00

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

PR NewswireDec 17 19:00

BTIG Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62

Futu NewsDec 17 09:32 · Ratings

IDEAYA Biosciences: Promising Pipeline and Strong Financials Make for a Buy Recommendation

TipRanksDec 17 08:46 · Ratings

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

PR NewswireDec 16 19:00

IDEAYA Biosciences (NASDAQ:IDYA) Pulls Back 9.2% This Week, but Still Delivers Shareholders Solid 23% CAGR Over 5 Years

Yahoo FinanceDec 16 18:43

Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx

Seeking AlphaDec 14 04:00

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

PR NewswireDec 11 19:00

Express News | IDEAYA Announces First-Patient-in for Phase 1 Clinical Trial Evaluating Ide161 in Combination With Keytruda® (Pembrolizumab) in Patients With Endometrial Cancer

BreakingsDec 10 19:00